Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 10,556 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Interventions: Prospective observational cohorts; Other
Lead sponsor: Edgar Jaeggi; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 15 more

Conditions: Chronic Rhinosinusitis With Nasal Polyposis
Interventions: DUPIXENT®; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 48
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 42 more

Conditions: Duchenne Muscular Dystrophy
Interventions: IGF-1; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cystic Fibrosis
Interventions: VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 28
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more

Conditions: Lung Cancer
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 2,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 431
States / cities: Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 283 more

Conditions: COVID19
Interventions: RD-X19, Sham; Device
Lead sponsor: EmitBio Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Clearwater, Florida • Miami, Florida • Kalamazoo, Michigan + 6 more

Conditions: Myelodysplastic Syndromes
Interventions: Pracinostat, Azacitidine; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 25
States / cities: Duarte, California • San Diego, California • Augusta, Georgia + 21 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more

Conditions: Neutropenia, Breast Cancer
Interventions: SPI-2012, Pegfilgrastim, Docetaxel, Cyclophosphamide; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 49
States / cities: Tucson, Arizona • Yuma, Arizona • Hot Springs, Arkansas + 46 more

Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Interventions: INKmune; Biological
Lead sponsor: Inmune Bio, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • Las Vegas, Nevada • Cincinnati, Ohio + 4 more

Conditions: Pain
Interventions: EXPAREL, Bupivacaine; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Fremont, California • Loma Linda, California • Fort Lauderdale, Florida + 13 more

Conditions: Restless Legs Syndrome
Interventions: Pramipexole; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 52
States / cities: Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 47 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Concord, California • Sacramento, California + 17 more

Conditions: Dermatomyositis
Interventions: Prednisone, Methotrexate, Etanercept; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years to 16 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions: ABT-751, quality-of-life assessment; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 8 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Conditions: Sedation
Interventions: Isoflurane, Propofol, Isoflurane (run-ins); Drug
Lead sponsor: Sedana Medical; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Menopausal and Female Climacteric States
Interventions: Other: Placebo, GSK232802, PREMARIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more

Conditions: Docosohexaenoic Acid Supplementation of Mothers to
Interventions: Expecta 200 mg, Expecta 1 gram; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Protein C Deficiency
Interventions: Protein C Concentrate (Human) Vapor Heated; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more

Conditions: Fragile X Syndrome
Interventions: Baclofen, Memantine, Roflumilast, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 103
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more

Conditions: Depression
Interventions: 6(S)-5-MTHF(Deplin), Placebo; Other
Lead sponsor: George I. Papakostas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Search by objective public record fields.

Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

S9925: Collecting and Storing Samples From Patients With Lung Cancer

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Study of INKmune in Patients With mCRPC (CaRe Prostate)

Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty

A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

DHA Supplementation for Lactating Mothers

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder